Charmaine Lykins - 29 Nov 2021 Form 3 Insider Report for Karuna Therapeutics, Inc.

Role
Chief Commercial Officer
Signature
/s/ Charmaine Lykins
Issuer symbol
N/A
Transactions as of
29 Nov 2021
Net transactions value
$0
Form type
3
Filing time
30 Nov 2021, 16:11:24 UTC
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding KRTX Stock Option (Right to Buy) 29 Nov 2021 Common Stock 75,000 $125.52 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of this option shall vest on November 29, 2022, and the remaining 75% shall vest in twelve equal three-month installments over the following three years, subject to continued service through such dates.

Remarks:

Exhibit 24 - Power of Attorney